Drug combo helps women with early breast cancer

Dec 10, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- A new study finds that using two drugs, Herceptin (her-SEPT-in) and Tykerb (TIE-curb), more than doubles the number of women with early breast cancer whose tumors disappear before they are scheduled to have surgery to remove them.

These drugs target a that is overproduced in about one-fourth of all breast cancers. In the study, about 450 women getting chemotherapy were also given Herceptin or Tykerb or both drugs. Half of the women on the combination saw their tumors disappear versus only 20 percent of those taking either drug alone.

GlaxoSmithKline PLC makes Tykerb. Roche's Genentech division makes Herceptin. Doctors discussed the study Friday at a conference in San Antonio.

Explore further: 'Stem cell' test could identify most aggressive breast cancers

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novel drug combo improves breast cancer survival

Dec 11, 2009

(AP) -- Some women with very advanced breast cancer may have a new treatment option. A combination of two drugs that more precisely target tumors significantly extended the lives of women who had stopped responding to other ...

Drug combination shrinks breast cancer metastases in brain

Dec 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Herceptin targets breast cancer stem cells

Jul 09, 2008

A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, according to a new study from the University of Michigan Comprehensive ...

Recommended for you

How much overdetection is acceptable in cancer screening?

3 hours ago

People have highly variable views on how much overdetection is acceptable in cancer screening, finds a UK survey in The BMJ this week. The authors say invitations for screening "should include clear information on the li ...

Protein may be key to cancer's deadly resurgences

13 hours ago

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.